Ling Zhang

Ling Zhang is a highly experienced scientist specializing in antibody discovery and development. Currently serving as a Consultant at QLSF Biotherapeutics, Inc. since April 2024, Ling Zhang focuses on antibody screening from hybridoma and phage display, as well as VHH antibody reformatting. Prior to this role, Ling Zhang worked as a Senior Scientist at Bristol Myers Squibb, where responsibilities included generating antibodies for therapeutic applications, high-throughput screening, and leading new technology development in immunization. Previous positions include Senior Scientist at Kriya Therapeutics, Scientist II at LakePharma, Inc., and roles at UCSF where research involved CRISPR/Cas9 technologies. Educational qualifications include a Ph.D. in Biophysics from Tsinghua University, a Master’s in Pharmacology from Peking Union Medical College, and a Bachelor’s in Biochemistry from Jilin University.